started · updated
EASD Congress highlights semaglutide benefits and AI diabetes screening
At the 62nd EASD Congress in Milan, several medical advancements and public health initiatives were highlighted. A major focus was the clinical profile of semaglutide, which has been recognized in the ESC 2026 Guidelines (recommendation 1A) for its ability to improve cardiovascular outcomes in patients with diabetes and kidney disease. Data presented showed semaglutide reduces major cardiovascular events by 26%, non-fatal strokes by 39%, and composite renal risk by 24%, while improving functional capacity by 13%.
Research into early diagnosis was also prominent. A new AI model developed by Thymia and RMIT University can identify signs of type 2 diabetes by analyzing just 20 seconds of voice recordings, detecting changes in hoarseness and breath control. Additionally, the Dexcom State of Type 2 Report indicated that 89% of healthcare professionals believe continuous glucose monitoring (CGM) aids in assessing treatment adherence.
Regarding pregnancy safety, a metanalysis of over 43,000 women found no significant association between GLP-1 receptor agonist exposure and risks of preterm birth, fetal death, or pre-eclampsia. However, researchers noted a 31% frequency of early pregnancy loss in exposed women, though they cautioned that data limitations make definitive conclusions difficult.
On a policy level, the European Commission launched the first EU Screening Week to encourage early detection of cardiovascular risk factors like blood pressure and cholesterol, aiming to mitigate the significant economic and health burden of heart disease in the EU.
Entities
Boehringer Ingelheim · Eli Lilly · Eli Lilly and Company · European Association for the Study of Diabetes · European Commission · Milan · National Health Service · Novo Nordisk · RMIT University · Salvatore De Cosmo · Thymia
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 5 SOURCES] Semaglutide is positioned in recommendation 1A in the ESC 2026 Guidelines for improving cardiovascular outcomes in patients with diabetes and kidney disease. www.ilpubblicista.it · www.supertvoristano.it · www.dialessandria.it · www.ilfattonisseno.it · quotidianodigela.it
- [○ 1 SOURCE] The number of people living with diabetes is projected to rise from 9.4 million in 2025 to 12.1 million by 2049.
- [● 10 SOURCES] AI models can identify signs of type 2 diabetes by analyzing 20-second voice recordings. www.egnews.it · www.corcianonline.it · canaledieci.it · www.salutedomani.com · quotidianodifoggia.it
- [○ 1 SOURCE] In 2025, 42% of new type 1 diabetes cases globally will involve children and adolescents aged 0 to 19.
- [○ 1 SOURCE] New EASD guidelines suggest extending continuous glucose monitoring (CGM) to all adults with type 2 diabetes, regardless of insulin treatment.
- [● 5 SOURCES] Semaglutide has demonstrated a 26% reduction in major cardiovascular events and a 39% reduction in non-fatal strokes. www.ilpubblicista.it · www.supertvoristano.it · www.dialessandria.it · www.ilfattonisseno.it · quotidianodigela.it
- [● 11 SOURCES] The 62nd EASD Congress is being held in Milan from September 28 to October 2. www.doctor33.it · www.egnews.it · www.ilpubblicista.it · www.corcianonline.it · www.dialessandria.it · +3 more
- [○ 1 SOURCE] The 2026 ADA/EASD Consensus Report moves toward early and intensive treatment for diabetes.
- [DISPUTED] A metanalysis reported early pregnancy loss was more frequent at 31% among women exposed to GLP-1 agonists, though authors noted data limitations. www.doctor33.it
- [● 4 SOURCES] Semaglutide has shown a 24% reduction in composite renal risk and a 13% improvement in functional capacity. www.ilpubblicista.it · www.supertvoristano.it · www.ilfattonisseno.it · quotidianodigela.it
- [DISPUTED] A metanalysis of over 43,000 women found no significant association between GLP-1 receptor agonist exposure and risks of preterm birth, fetal death, or pre-eclampsia. www.doctor33.it
- [● 4 SOURCES] Researchers from Thymia and RMIT University developed an AI model to detect type 2 diabetes through voice changes like hoarseness and breath control. www.salutedomani.com · www.egnews.it · www.corcianonline.it · quotidianodifoggia.it